Elopag 50 — Eltrombopag 50 mg, 14 product-page.units_short, Everest
100% original product

Elopag 50 (Eltrombopag) 50 mg Tablets

6376₴ 7695₴ -17%

Elopag 50 mg (Eltrombopag) is a thrombopoietin receptor agonist used to stimulate platelet production in conditions associated with thrombocytopenia.

Manufacturer: Everest Pharmaceuticals Ltd.. Each pack contains 14 tablets. The drug helps increase platelet counts in patients with chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C.

Key Feature:

The 50 mg strength is often used as a starting or maintenance dose to achieve a safe platelet count and reduce bleeding risk under regular laboratory monitoring.

Indicated for adult patients and, in some cases, pediatric patients as prescribed by a physician for the following conditions:

  • 🔹 Chronic Immune Thrombocytopenia (ITP): in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy.
  • 🔹 Thrombocytopenia associated with chronic hepatitis C: to enable initiation and continuation of antiviral therapy.
  • 🔹 Severe Aplastic Anemia: in patients with inadequate response to immunosuppressive treatment.

Packaging: 50 mg tablets.

⚠️ ADMINISTRATION PROTOCOL:

  • Starting Dose: Determined individually by the physician depending on diagnosis, platelet count, age, and ethnic considerations.
  • Food Intake: Take on an empty stomach or with a meal low in calcium.
  • Important: Do not take together with dairy products, antacids, or supplements containing calcium, magnesium, aluminum, iron, selenium, or zinc. A gap of at least 4 hours should be maintained.
  • Monitoring: Regular monitoring of platelet count, liver function tests, and complete blood count is required.
  • Note: Dose adjustments should only be made by the treating physician based on laboratory findings.
  • Hypersensitivity to Eltrombopag or any component of the product.
  • Use with caution in patients with hepatic impairment.
  • High risk of thrombosis and thromboembolic complications.
  • Pregnancy and breastfeeding — use only when clearly indicated by a physician.

Common and clinically important adverse reactions include:

  • 🩸 Blood/Vascular: Increased risk of thrombosis and thromboembolism.
  • 📉 Gastrointestinal: Nausea, diarrhea, abdominal pain, decreased appetite.
  • 🧪 Liver: Increased ALT, AST, bilirubin, possible hepatotoxicity.
  • 💢 General: Headache, weakness, fatigue.
  • 👁 Other: Possible development or progression of cataracts with long-term use.
Active ingredient
Manufacturer
Everest
Dosage 50 mg
Dosage form Tablets
Tablets per pack 14
100% original product
Delivery across Ukraine
Alternatives

Similar products

Elopag 25 25 mg Everest
View
Everest

Elopag 25

25 mg 14 tablets
4397₴ 5277₴
Customer reviews

What Customers Say

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00